/ /

Advances

New target could predict melanomaNew information could eventually help identify a high-risk population before they get cancer — even prevent skin cancer’s onset.
The oral pipeline for psoriasisOral options in the pipeline for psoriasis show promise.
Combination therapy shows promising phase 2 resultsData suggest photodynamic therapy with the investigational topical methyl aminolevulinate may be an effective treatment for patients with severe facial acne.
Studies you may have missedOne expert summarizes science outside of dermatology that offers insight into the genetic toll of sun damage, the potential skin-protecting effects of vitamin B3, the sun-exposure threat posed by automobile side windows and more.
FDA approves drug for pregnant women with HIVFDA recently approved an expansion to the prescribing information for darunavir (Prezista, Janssen Therapeutics), to treat pregnant women with HIV.
Ixekizumab effective psoriasis treatment through 60 weeksResults from three phase 3 trials, suggest ixekizumab (Talz, Eli Lilly & Company) is effective through 60 weeks of treatment among patients with moderate-to-severe plaque psoriasis.
New Products: FDA approves combination regimen to treat advanced RCCOther products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more.
App aims to supplement physician visits for acneThe acne app offers a free and immediate analysis of acne type and severity; develops an individualized acne control plan; and monitors users’ progress. It aims to help consumers diagnose, treat, manage and prevent acne.
FDA approves first once-monthly injection to lower cholesterolFDA approved evolocumab (Repatha, Amgen) Pushtronex system, the first monthly single-dose injection of a PCSK9 inhibitor. Repatha was already approved by FDA as the only PCSK9 inhibitor with a monthly dose last August.
Dupilumab demonstrates promising resultsThe systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.

Poll

View Results